Zhende Medical: The US tariff policy has no impact on the company yet, and the Mexican production base may be completed next year | Direct hit on earnings conference
①Zhende Medical's chairman Lu Jianguo introduced at the earnings conference that the construction of the new production base in Mexico is expected to be completed next year; ② Zhende Medical explained the company's Q3 operation situation, with further decrease in revenue from isolation protective equipment.
yabao pharmaceutical group saw a year-on-year increase in revenue for two children's medications. Revenue for the injection of Benatuostin hydrochloride has not yet stopped declining. | Directly focusing on the earnings conference
At the earnings conference, yabao pharmaceutical group stated that in the first three quarters of this year, the company's pediatric products revenue increased year-on-year. The company's secretary of the board also mentioned that while the revenue of Tenatoprazole Hydrochloride Injection decreased, sales volume increased, and predicted that the 'income decline in this category will continue to narrow within the year'. yabao pharmaceutical group also provided explanations on the progress of the company's R&D pipeline, share buybacks, and other situations.
The trend of social security fund holdings has been exposed: in the third quarter, 123 new stocks were added to the top ten list of public shareholders, with guangxi energy and zhongman petroleum and natural gas group corp.,ltd. adding a large number of i
①As the third-quarter report is disclosed, the holdings trend of the social security fund in the third quarter is also revealed; ②The list of the top ten circulating shareholders of 123 new stocks; ③Attached is the list of A-share institutions with the highest number of new holdings by social security funds in the third quarter (see table).
SSE successively inquired about listed companies' 'cross-border mergers and acquisitions' with a focus on valuation and performance bets.
Dalian bio-chem's cross-border increased investment in Xinhui Lian attracted the attention of the Shanghai Stock Exchange. This time, Xinhui Lian's pre-investment valuation was 0.8 billion yuan, priced at 0.7 billion yuan, but Dalian bio-chem's investment in Xinhui Lian only involves part of Xinhui Lian's assets, not including the development of "wafer bonding machine" business. Dongguan Huali Industries and Jiangxi Lianchuang Opto-Electronic Science&Technology have recently been questioned by the Shanghai Stock Exchange, all involving high premium acquisitions, performance guarantees, and so on.
china kings resources group Q3 net profit decreased by more than 30%, rare interim report distributing dividends|interpretations
①In the peak season, the company's Q3 net income attributable to shareholders was less than 83 million yuan; ②The company's net profit growth rate has been declining by quarter, far from the institutional forecast target; ③The main reasons for the decline are the shutdown of mines and the downturn in the prosperity of new products such as lithium carbonate; ④The company is optimistic about Q4 expectations, expecting an increase in sales volume and prices on a month-on-month basis.
Overseas new production capacity entering the release period. Jiangsu General Science Technology's Q3 revenue increased by more than 30% year-on-year | Financial interpretations
①Overseas new production capacity are gradually put into operation, semi-steel tire orders are full, jiangsu general science technology's revenue scale continues to expand; ②Company officials stated that in Q3 of this year, the company faced issues such as rising raw materials, marine transportation costs, and high cost amortization. As we enter the fourth quarter, the cost pressure has eased.